Back to School: How biopharma can reboot drug development. Access exclusive analysis here

North American Vaccine, Baxter, BioChem deal

The companies reduced by $0.27 to $6.73 the per-share consideration NVX shareholders will receive from BAX under BAX's proposed acquisition

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE